Related Experiment Video
Updated: Nov 17, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology
1Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland berna.oezdemir@insel.ch.
Abstract:
Despite a significant amount of data on incidence and therapy of immune-related adverse events affecting virtually all organ systems, the potential impact of immune checkpoint inhibitors (ICIs) on gonadal function has not been sufficiently studied. The limited evidence available suggests that ICI-related primary hypogonadism due to orchitis as well as secondary hypogonadism due to hypophysitis are a potential risk for infertility. A systematic investigation of gonadal function under ICIs is warranted given the increasing application of ICIs in the adjuvant setting, among young adults and children and the possible influence of sex hormone levels on the efficacy and toxicity of ICIs.
Insights
Immune checkpoint inhibitors (ICIs) may impact gonadal function, increasing infertility risks. Further research is needed to understand these effects, especially in young patients receiving adjuvant therapy.
Area of Science:
- Oncology
- Endocrinology
- Immunology
Background:
- Immune checkpoint inhibitors (ICIs) are increasingly used for cancer treatment.
- Immune-related adverse events (irAEs) affect multiple organ systems.
- The impact of ICIs on gonadal function remains understudied.
Purpose of the Study:
- To investigate the effects of ICIs on gonadal function.
- To assess the risk of hypogonadism and infertility associated with ICI therapy.
- To highlight the need for systematic evaluation of gonadal function in patients receiving ICIs.
Main Methods:
- Systematic review of existing literature.
- Analysis of reported cases of hypogonadism (primary and secondary) in patients on ICIs.
- Evaluation of potential mechanisms, including orchitis and hypophysitis.
Main Results:
- Limited evidence suggests ICIs can cause primary hypogonadism (orchitis) and secondary hypogonadism (hypophysitis).
- These conditions pose a risk for infertility in patients treated with ICIs.
- The influence of sex hormones on ICI efficacy and toxicity is a potential concern.
Conclusions:
- ICI therapy carries a potential risk of gonadal dysfunction and infertility.
- Systematic monitoring of gonadal function is crucial for patients undergoing ICI treatment.
- Further research is warranted, particularly in young populations and those receiving adjuvant therapy.
More Related Videos
08:17A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
Published on: August 15, 2019
09:04Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Related Concept Videos
Tumor Immunotherapy
Infertility in Males
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Infertility in Females
Endometriosis, a condition characterized by abnormal growth of...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...